prodchem
Aug 10, 2026
Switzerland-based pharmaceutical manufacturer Lonza is taking another major step in reshaping its business portfolio by divesting its Capsules & Health Ingredients (CHI) division to US private equity firm Lone Star Funds.
The transaction, announced in March 2026, values the business at CHF 2.3 billion (approximately $3 billion) at closing. Lonza will receive around CHF 1.7 billion ($2.2 billion) in upfront proceeds while retaining a 40% stake in the business, along with preferential participation in a future exit. The transaction is expected to close in the second half of 2026, subject to the required approvals.
The deal is more than a financial transaction. It represents the final major step in Lonza’s strategy to transform itself into a focused, pure-play contract development and manufacturing organization (CDMO).
Lonza has been restructuring its portfolio under its broader “One Lonza” strategy, with the objective of concentrating resources on its core CDMO operations.
The company had been evaluating strategic options for the CHI business since 2024. By separating capsules and health ingredients from its CDMO operations, Lonza can focus capital and management attention on pharmaceutical development and manufacturing services, particularly in higher-growth areas such as biologics and specialized modalities.
The divestment also provides Lonza with significant capital that can be redirected toward organic growth and targeted acquisitions.
The transaction covers Lonza’s Capsules & Health Ingredients business, which serves pharmaceutical and healthcare customers through capsule technologies and related health-ingredient solutions.
Under the agreement:
Enterprise value is CHF 2.3 billion.
Lonza will receive approximately CHF 1.7 billion in upfront cash.
Lonza will retain a 40% stake after closing.
Lonza will receive additional preferential participation in a future exit.
Total undiscounted proceeds are expected to reach CHF 3 billion or more over time.
Closing is expected during H2 2026.
This structure allows Lonza to unlock substantial value from the business while maintaining exposure to its future performance.
For Lone Star Funds, the acquisition provides exposure to an established global healthcare manufacturing platform with specialized capabilities and established customer relationships.
The CHI business also operates in markets benefiting from evolving pharmaceutical and healthcare trends. Lonza has highlighted opportunities in oral solid dosage products, including growing interest in oral alternatives to injectable therapies and new applications involving peptides, live biotherapeutics and other complex molecules.
Private equity ownership could give the business a different capital-allocation strategy, potentially supporting operational improvements, acquisitions, geographic expansion, or further investment in specialized capsule technologies.
The divestment marks a significant change in Lonza's corporate identity.
Following the transaction, Lonza will be more tightly focused on CDMO activities, providing development and manufacturing services to pharmaceutical and biotechnology companies.
The company has indicated that the upfront proceeds will be used for additional organic growth opportunities and bolt-on acquisitions. Lonza also plans to return CHF 500 million to shareholders through a share buyback after receiving the transaction proceeds.
This gives Lonza greater financial flexibility to invest in its core operations while maintaining shareholder returns.
The transaction could have implications beyond Lonza and Lone Star.
Capsules and oral dosage technologies are important components of pharmaceutical supply chains. Changes in ownership can influence investment priorities, manufacturing capacity, technology development, and supplier relationships.
For pharmaceutical manufacturers and procurement teams, the key issue will be maintaining continuity during the transition. Customers will likely monitor whether ownership changes affect production locations, contract structures, lead times, pricing, or capacity commitments.
At the same time, new ownership could create opportunities for investment in manufacturing capacity and technology if Lone Star pursues an expansion-oriented strategy.
Pharmaceutical procurement teams should closely monitor several areas as the transaction progresses toward closing:
Existing supply agreements should be reviewed to understand whether ownership changes trigger any contractual requirements or renegotiation provisions.
Customers relying on specific capsule manufacturing facilities should monitor capacity allocation and future investment plans.
A private equity-backed business may pursue operational improvements and portfolio optimization. This could eventually influence pricing and commercial terms.
Companies should assess whether alternative suppliers are available for critical capsule formats and health ingredients in case production strategies change.
Future investment in capsule technologies could create new opportunities for pharmaceutical manufacturers, particularly in complex oral dosage forms.
Lonza's transaction reflects a wider trend among pharmaceutical suppliers: companies are increasingly separating non-core assets from their main operations and concentrating investment around specialized, higher-value capabilities.
For Lonza, the objective is clear — build a more focused CDMO business capable of benefiting from continued outsourcing by pharmaceutical and biotechnology companies.
For Lone Star, the acquisition offers an opportunity to develop a specialized healthcare platform outside Lonza's core CDMO structure.
Lonza's sale of its Capsules & Health Ingredients business to Lone Star Funds is a significant restructuring transaction in the global pharmaceutical supply chain.
With an enterprise value of CHF 2.3 billion, substantial upfront proceeds for Lonza, and continued ownership of 40% of the business, the transaction provides both companies with strategic flexibility.
For Lonza, the deal completes a major transformation toward a pure-play CDMO model. For Lone Star, it creates an opportunity to build and expand a specialized healthcare manufacturing business.
The next important stage will be the expected H2 2026 closing and the strategy adopted by the new ownership. Pharmaceutical manufacturers and procurement teams should therefore monitor capacity, contracts, pricing, and investment decisions as the transition progresses.
Featured Product
Found this useful?
Continue Reading
Industrial sector demand accounts for more than 80% of basic and specialty chemical consumption, creating important implications for chemical sourcing, pricing and procurement strategies. Understand how industrial input markets influence purchasing decisions across chemical supply chains.
Eastman's Q2 earnings beat provides a positive near-term signal, but cautious discretionary-demand commentary and continued Fibers pressure suggest that the stronger result should not automatically be interpreted as evidence of a broad-based demand recovery.
Food additive regulation is becoming increasingly fragmented as states pursue their own approaches to food chemicals and dyes. For chemical traders, importers and procurement teams, shifting state policies can reshape product demand, compliance priorities and market access.
